Theorem Clinical Research

Actavis

Actavis signs option to acquire Rhythm subsidiary

Thursday, October 23, 2014 01:08 PM

Actavis, a Dublin, Ireland-based global specialty pharmaceutical company, has been granted an exclusive option to acquire Rhythm subsidiary Rhythm Health, a Boston, Mass.-based biopharmaceutical company developing relamorelin (RM-131), a peptide ghrelin agonist, for the treatment of diabetic gastroparesis and other GI functional disorders.

More... »


Actavis to acquire Durata Therapeutics

Monday, October 6, 2014 04:00 PM

Actavis, a global specialty pharmaceutical company based in Dublin, Ireland, and Durata Therapeutics, an innovative pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses, headquartered in Chicago, Ill., have entered into a definitive merger agreement.

More... »


Actavis completes acquisition of Furiex Pharmaceuticals

Friday, July 4, 2014 08:00 AM

Forest Laboratories, a subsidiary of Actavis, has successfully completed its acquisition of Furiex Pharmaceuticals in an all-cash transaction valued at approximately $1.1 billion, and up to approximately $360 million in a Contingent Value Right (CVR) that may be payable based on the status of eluxadoline, Furiex's lead product, as a controlled drug following approval.

More... »

Actavis completes Forest Laboratories acquisition

Tuesday, July 1, 2014 10:50 AM

Dublin-based Actavis has completed its acquisition of Forest Laboratories in a cash and equity transaction valued at approximately $28 billion. The combination creates a specialty pharmaceutical company with annual revenues of more than $15 billion anticipated for 2015.

More... »

Forest Labs’ $1.46 billion acquisition of Furiex strengthens GI business

Tuesday, April 29, 2014 03:24 PM

The pharmaceutical industry’s shopping spree for specific disease expertise or scale continued this week as Forest Laboratories announced plans to acquire Furiex Pharmaceuticals for up to $1.46 billion, including milestone payments.

More... »

Actavis launches Asia Pacific regional headquarters in Singapore

Friday, April 4, 2014 12:01 PM

Actavis, a global specialty pharmaceutical company, has opened its new regional office in Singapore, which will serve as the headquarters for the company's Asia Pacific and Africa (APACA) region.

More... »

Actavis to acquire Forest Laboratories for $25 billion

Tuesday, February 18, 2014 10:39 AM

Dublin-based Actavis has agreed to acquire Forest Laboratories of New York for a combination of cash and equity valued at approximately $25 billion.

More... »

Aurobindo acquires commercial operations in seven countries from Actavis

Monday, January 20, 2014 11:59 AM

Aurobindo Pharma, a Hyderabad, India-based manufacturer of generic pharmaceuticals and active pharmaceutical ingredients, has signed a binding offer to acquire commercial operations in seven Western European countries from Actavis, a Dublin, Ireland-based global, integrated specialty pharmaceutical company. Closing of the transaction is conditional on certain antitrust approvals and completion of employee consultation processes.

More... »

FTC seeks information on proposed Actavis acquisition of Warner Chilcott

Monday, July 15, 2013 01:17 PM

Actavis, a globally integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products, and Warner Chilcott, a supplier of inhalation drug development, delivery and supply capabilities, have both received a request for additional information from the Federal Trade Commission (FTC) in connection with Actavis' pending acquisition of Warner Chilcott. The information request was issued under notification requirements of the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR Act").

More... »

Actavis to expand Florida manufacturing facility, create 220 jobs

Wednesday, March 27, 2013 10:55 AM

Actavis, a specialty pharmaceutical company formerly known as Watson Pharmaceuticals, plans to expand its pharmaceutical manufacturing and warehousing facilities in Davie, Fla., resulting in the creation of 220 jobs.

More... »

CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

October 20

Toronto Star, with FDA data, exposes weaknesses in Health Canada's clinical trial, inspection oversight

Crowdsourcing effort aims to fund updated online social media guide for sponsor interaction with patients

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

September

Today's fastest, most economical sponsors
Standout sponsors reveal how they shorten regulatory, clinical cycle times

From the trenches: Sites' eye view of state of the industry
CW’s first site focus groups uncover frustration with 'progress,' but a passion for their mission

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs